// App-Quantinova.ai

: Tolerability of Acalabrutinib after Prior Ibrutinib Treatment in Patients with CLL: Experience of a Tertiary Cancer Care Center

Researchers

Presenter

  • Adam J DiPippo

Principal Investigators

  • Alicia McGhie

  • Jenessa Lee

  • Philip A. Thompson

  • Nitin Jain

  • William G. Wierda

  • Hagop Kantarjian

  • Alessandra Ferrajoli

Medical Centers

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

  • Department of Leukemia, MD Anderson Cancer Center, Houston, TX

  • The University of Texas M.D. Anderson Cancer Center, Houston, TX

  • Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • ACP-196

  • Ibrutinib

Outcome

  • N/A

Study Design

  • Multinational

  • Tolerability

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved